Lenovo to Be Main Sponsor of Red Bull Illume Image Quest 2021
25.2.2021 17:00:00 EET | Business Wire | Press release
The world’s greatest adventure and action sports imagery contest, Red Bull Illume® returns in 2021 with global technology leader, Lenovo™, as its Exclusive Computing Sponsor. A showcase for the best of adventure and action sports imagery, the competition is expected once again to receive tens of thousands of entries from around the world including some of the most creative and extreme images ever captured. As part of this two-year partnership, Lenovo will be involved through brand, product placement and logo incorporation for both online and in-person content, prizes for finalists and winners, as well as having promotional access to the incredible contest imagery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005071/en/
Austrian photographer Philip Platzer gets the perfect in-air shot of Red Bull Skydive teammate, Marco Fürst, participating in The Megaswing Project. (Photo: Philip Platzer/ Red Bull Illume)
Lenovo enables a more inclusive and inspired world for all through smarter technology, so it’s fitting Lenovo should present this year’s Best of Instagram category that opens up the competition to all. Unlike the contest’s nine other categories which are adjudicated by a panel of 50 photo and digital experts from around the world, the finalists and category winners for Best of Instagram by Lenovo are selected through public voting. Each month, from March 1 to July 31, 2021, there will be five still and five moving images pre-selected by an internal jury which are put out to a community vote. The top choices from each month will become official Red Bull Illume Image Quest 2021 Finalists; from these, a final online vote will decide the best still image and the best moving image, to be crowned as Lenovo’s Best of Instagram Category Winners. Anyone can submit their moving or still images on Instagram by tagging @redbullillume and #rbi21submission.
The Overall Winner of Red Bull Illume Image Quest 2021 is selected from all the category winners by the international judging panel. There is a total of 10 categories which are created to truly shine a light on the lifestyle and culture behind today’s professional and amateur content creators and their dedication to the craft. Each edition of the contest brings out a new level of never-seen-before creativity, and this edition is bound to be full of imagery that pushes the boundaries of content creation in adventure and action sports imagery.
Along with receiving well-earned career exposure as an official Red Bull Illume winner, their work will tour the globe, illuminated on huge lightboxes. The winners are also awarded prize packages that include trophies and the latest Lenovo products to power even more creative self-expression. Their work will be included in the official Red Bull Illume photobook and showcased during the winner award ceremony planned for November 2021 and attended by Ulrich Grill, the founder of the Red Bull Illume Image Quest.
“Lenovo is proud to support the sixth edition of Red Bull Illume Image Quest that brings together photographers and content creators whose bold work continually inspires us,” said Matt Bereda, Vice President of Global Consumer Marketing, PCs and Smart Devices, Lenovo. “We see many of our consumer PC, smart home, and tablet customers are passionate hobbyists. They enjoy photography and digital storytelling, and not all of them are paid professionals—they just love capturing and enhancing imagery to share with others and hang on their walls. If this new normal has taught us anything about our world and ourselves, it’s that we’re resilient, our technology is adaptable, and that making meaningful connections with others through shared creative pursuits are the bright spots in life that really matter.”
“Red Bull Illume is like the Oscars of adventure and action sports imagery and we are extremely proud to have Lenovo join the 2021 edition,” said Ulrich Grill, Founder of Red Bull Illume. “This contest honors the creativity and hard work that goes into producing one-of-a-kind imagery and Lenovo gives content creators the tools they need to express their unique ideas.”
A shared dedication to transformative experiences and using innovative technology to push boundaries makes Red Bull Illume and Lenovo ideal partners. Meaningful innovation is essential to advancing photo technologies and solidifying image capture as an artform. Similarly, Lenovo innovation provides digital creators with better photo management and enhancement experiences and smarter technology so they can build bigger for a more creative world – making consumer products, services, and software solutions more attuned to the unique needs of modern content creators.
The contest is open for submissions from March 1 to July 31, 2021. It is free for anyone to enter and voting is open to all on redbullillume.com. To view previous winning images, check out the gallery, here.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy and sustainable digital society. By designing, engineering and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more visit https://www.lenovo.com, follow us on LinkedIn, Facebook, Twitter, YouTube, Instagram, Weibo and read about the latest news via our StoryHub.
About Red Bull Illume
The Image Quest 2021 is the sixth edition bringing together the amazing work of photographers and content creators from around the world. In 2019, a record-breaking 59,551 images were submitted by thousands of creators from countries all around the world. Submissions for the contest will take place from March 1 to July 31, 2021 and can be entered on redbullillume.com and on Instagram. A judging panel of 50 photo editors and digital experts will select the Finalists, Category Winners and an Overall Winner, to be unveiled at the Winner Award Ceremony in November 2021. Follow us on Instagram, Facebook, Twitter, YouTube and Pinterest.
LENOVO is a trademark of Lenovo. RED BULL ILLUME is a trademark of Red Bull GmbH. Instagram is a trademark of Instagram, LLC. All other trademarks are the property of their respective owners. ©2021, Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005071/en/
Contact information
Wendy Fung
wfung@zenogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom